JPWO2023056446A5 - - Google Patents
Info
- Publication number
- JPWO2023056446A5 JPWO2023056446A5 JP2024519313A JP2024519313A JPWO2023056446A5 JP WO2023056446 A5 JPWO2023056446 A5 JP WO2023056446A5 JP 2024519313 A JP2024519313 A JP 2024519313A JP 2024519313 A JP2024519313 A JP 2024519313A JP WO2023056446 A5 JPWO2023056446 A5 JP WO2023056446A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- modified oligonucleotide
- modified
- disease
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163251562P | 2021-10-01 | 2021-10-01 | |
| US63/251,562 | 2021-10-01 | ||
| US202163287960P | 2021-12-09 | 2021-12-09 | |
| US63/287,960 | 2021-12-09 | ||
| PCT/US2022/077389 WO2023056446A1 (en) | 2021-10-01 | 2022-09-30 | Angiotensinogen-modulating compositions and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024536146A JP2024536146A (ja) | 2024-10-04 |
| JP2024536146A5 JP2024536146A5 (https=) | 2025-10-07 |
| JPWO2023056446A5 true JPWO2023056446A5 (https=) | 2025-10-07 |
Family
ID=85783681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024519313A Pending JP2024536146A (ja) | 2021-10-01 | 2022-09-30 | アンジオテンシノーゲンを調節する組成物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240401045A1 (https=) |
| EP (1) | EP4408525A4 (https=) |
| JP (1) | JP2024536146A (https=) |
| KR (1) | KR20240099244A (https=) |
| AU (1) | AU2022355198A1 (https=) |
| CA (1) | CA3233330A1 (https=) |
| WO (1) | WO2023056446A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
| PE20241340A1 (es) * | 2021-11-24 | 2024-07-03 | Adarx Pharmaceuticals Inc | Composiciones moduladoras de complemento del factor b y metodos de uso de estas |
| WO2025024283A1 (en) * | 2023-07-21 | 2025-01-30 | Adarx Pharmaceuticals, Inc. | Coagulation factor xi-modulating compositions and methods of use thereof |
| CN119876130A (zh) * | 2023-10-23 | 2025-04-25 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3215908A1 (en) * | 2014-05-22 | 2015-11-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
| CN113817735A (zh) * | 2015-10-08 | 2021-12-21 | Ionis制药公司 | 用于调节血管紧张素原表达的化合物和方法 |
| TWI851574B (zh) * | 2018-05-14 | 2024-08-11 | 美商阿尼拉製藥公司 | 血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法 |
| WO2022221457A1 (en) * | 2021-04-13 | 2022-10-20 | Adarx Pharmaceuticals, Inc. | Rna silencing agents and methods of use |
| TW202405171A (zh) * | 2022-04-01 | 2024-02-01 | 美商雅迪克斯製藥公司 | 血管收縮素原調節組合物及其使用方法 |
-
2022
- 2022-09-30 US US18/697,165 patent/US20240401045A1/en active Pending
- 2022-09-30 EP EP22877626.6A patent/EP4408525A4/en active Pending
- 2022-09-30 WO PCT/US2022/077389 patent/WO2023056446A1/en not_active Ceased
- 2022-09-30 AU AU2022355198A patent/AU2022355198A1/en active Pending
- 2022-09-30 JP JP2024519313A patent/JP2024536146A/ja active Pending
- 2022-09-30 CA CA3233330A patent/CA3233330A1/en active Pending
- 2022-09-30 KR KR1020247014615A patent/KR20240099244A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018530325A5 (https=) | ||
| US20200385735A1 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP2021074021A5 (https=) | ||
| JP2018199700A5 (https=) | ||
| JP7478210B2 (ja) | 修飾オリゴヌクレオチド及び使用方法 | |
| JP2021512629A5 (https=) | ||
| JPWO2019157531A5 (https=) | ||
| JP2021090458A5 (https=) | ||
| JP2012505660A5 (https=) | ||
| JPH08508491A (ja) | ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド | |
| IL277970B1 (en) | Oligomeric compounds comprising modified oligonucleotides and conjugate groups for use in treating end stage renal disease, chronic kidney disease, and coronary artery disease | |
| JP2004506606A (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
| CA2106819C (en) | Oligoribonucleotide and ribozyme analogs with terminal 3'-3' and/or 5'-5' linkages | |
| US5756478A (en) | Method for reducing toxicity of D-nucleoside analogs with L-nucleosides | |
| EP0906329B1 (en) | 2'-substituted nucleosides and oligonucleotide derivatives | |
| CZ295706B6 (cs) | Derivát 5´-deoxycytidinu, způsob jeho výroby a použití a farmaceutická kompozice a kit s jeho obsahem | |
| JPWO2023056446A5 (https=) | ||
| CN119137272A (zh) | 血管紧张素原调节组合物和其使用方法 | |
| JPWO2023049475A5 (https=) | ||
| JPWO2023192630A5 (https=) | ||
| JP2018518167A5 (https=) | ||
| JPH10508312A (ja) | アミノ酸核酸 | |
| JPWO2023056440A5 (https=) | ||
| TW202345861A (zh) | 經修飾之間隔體寡聚物及其使用方法 | |
| JPWO2023097291A5 (https=) |